Roquefort Therapeutics (ROQ) News Today → Democrats Push to Replace Dollar With Digital Coin, Control Currency. (From Monetary Gold) (Ad) Free ROQ Stock Alerts GBX 4.15 -0.10 (-2.35%) (As of 11:31 AM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11, 2024 | americanbankingnews.comRoquefort Therapeutics (LON:ROQ) Stock Price Down 5.5%April 26, 2024 | lse.co.ukEARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters GermanyApril 5, 2024 | msn.comUK Stocks: Here’s Why Roquefort (ROQ) Share Price is CrashingMarch 11, 2024 | lse.co.ukRoquefort celebrates "significant milestones" in cancer researchMarch 11, 2024 | uk.investing.comRoquefort Therapeutics reveals progress with liver and colorectal cancer programmesDecember 21, 2023 | seekingalpha.comNBSE NeuBase Therapeutics, Inc.November 6, 2023 | lse.co.ukRoquefort Therapeutics MK cell programme shows positive resultsSeptember 27, 2023 | proactiveinvestors.comRoquefort Therapeutics preparing targets for clinic as eyes commercial dealsSeptember 27, 2023 | proactiveinvestors.comRoquefort Therapeutics preparing targets for clinic as it eyes commercial dealsAugust 17, 2023 | finance.yahoo.comRoquefort Therapeutics seeks to lock in future value with anti-cancer therapeutic patentsAugust 9, 2023 | finance.yahoo.comRoquefort Therapeutics making headway with siRNAJune 29, 2023 | proactiveinvestors.comRoquefort Therapeutics highlights significant progress at AGMJune 22, 2023 | proactiveinvestors.comRoquefort Therapeutics hails significant pre-clinical resultsJune 22, 2023 | marketwatch.comRoquefort Therapeutics Makes Progress on Cancer TreatmentJune 16, 2023 | finance.yahoo.comRoquefort Therapeutics returns to the market with new study dataJune 13, 2023 | marketwatch.comRoquefort Therapeutics' Anti-Cancer MRNA Study Showed Positive ResultsJune 7, 2023 | marketwatch.comRoquefort Therapeutics Resumes Trading After Publishing 2022 ResultsJune 5, 2023 | proactiveinvestors.comRoquefort Therapeutics eyes second half progressMarch 13, 2023 | proactiveinvestors.comRoquefort Therapeutics has no exposure to SVBMarch 8, 2023 | proactiveinvestors.comRoquefort Therapeutics says new mRNA platform "fits very well"March 8, 2023 | proactiveinvestors.comRoquefort develops a fifth programme using a technology pioneered by Moderna and BioNTechMarch 6, 2023 | proactiveinvestors.comRoquefort Therapeutics establishes scientific advisory boardFebruary 22, 2023 | lse.co.ukRoquefort Thera Regulatory NewsFebruary 21, 2023 | barrons.comRoquefort Therapeutics PLCFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics inks Randox diagnostic dealFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics inks first strategic licensing deal with diagnostics firm RandoxJanuary 26, 2023 | finance.yahoo.comRoquefort Therapeutics demonstrates initial safety in two antibody programmesJanuary 24, 2023 | proactiveinvestors.comRoquefort Therapeutics demonstrates safety in two antibody programmesJanuary 24, 2023 | proactiveinvestors.comRoquefort Therapeutics cancer drugs enjoy pre-clinical successJanuary 9, 2023 | proactiveinvestors.comRoquefort Therapeutics CEO lays out strategy for 2023January 9, 2023 | proactiveinvestors.comRoquefort Therapeutics in out-licensing discussions with 'multiple' large bio-pharma companiesOctober 11, 2022 | proactiveinvestors.comRoquefort Therapeutics to present breakthrough RNA cancer study results at key conferenceOctober 11, 2022 | proactiveinvestors.comRoquefort Therapeutics explains the significance of its "very exciting" cancer drug study resultsSeptember 21, 2022 | msn.comStratford-upon-Avon company bought in multi-million pound dealSeptember 20, 2022 | msn.comBiotech firm Oncogeni acquired in £5.5m dealSeptember 17, 2022 | morningstar.comUK Retailers Drop After August Sales SlumpSeptember 16, 2022 | thetimes.co.ukRoquefort enlists Nobel prizewinner Sir Martin EvansSeptember 16, 2022 | proactiveinvestors.comFTSE 100 opens lower as world bank warns of recession.September 2, 2022 | uk.finance.yahoo.comRoquefort Therapeutics plc (ROQ.L)August 20, 2022 | investing.comRoquefort Investments PLC (ROQ)July 15, 2022 | finance.yahoo.comRoquefort Therapeutics PLC Announces Commencement of Trading on US OTCQB Venture Market Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden to Drop BOMBSHELL June 13th? (Ad)Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th! Click here now to see his shocking evidence. ROQ Media Mentions By Week ROQ Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ROQ News Sentiment▼0.000.55▲Average Medical News Sentiment ROQ News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ROQ Articles This Week▼10▲ROQ Articles Average Week Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VAL News IXI News IMM News EVG News FAB News BVX News RENE News PYC News SNG News OBI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:ROQ) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldDoes this make you sick?Allegiance GoldTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
